MARKET

ONVO

ONVO

Organovo Holding
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.760
-0.010
-0.57%
Closed 16:00 07/01 EDT
OPEN
1.760
PREV CLOSE
1.770
HIGH
1.883
LOW
1.750
VOLUME
11.83K
TURNOVER
15.82K
52 WEEK HIGH
9.56
52 WEEK LOW
1.710
MARKET CAP
15.33M
P/E (TTM)
-1.3381
1D
5D
1M
3M
1Y
5Y
Inovio Pharma, Bionano Genomics among health care stocks to join Russell Microcap Index; Tonix Pharma, iBio to leave
FTSE Russell has released a preliminary lists of companies set to join or leave the Russell Microcap Index as part of its 2022 annual reconstitution. Notable health care additions include: Inovio Pharma
Seekingalpha · 06/06 15:59
Organovo Says Co Achieves 3D Tissue Model For Crohn's Disease
Organovo Holdings, Inc. (NASDAQ:ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has
Benzinga · 05/17 12:12
Organovo Holdings to Proceed With Target Discovery, Validation for Crohn's Disease After Achieving 3D Tissue Model
MT Newswires · 05/17 11:46
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundationa...
GlobeNewswire · 03/01 13:05
BRIEF-Organovo And BICO Reach Licensing Agreement On Bioprinting Patents
reuters.com · 02/23 14:17
Organovo, BICO reach licensing deal on bioprinting patents
Organovo (NASDAQ:ONVO) and BICO reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Organovo and BICO were engaged in
Seekingalpha · 02/23 14:14
Organovo Reports Licensing Deal On Bioprinting Patents With CELLINK, No Terms Disclosed
Organovo Holdings, Inc. (NASDAQ:ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting.
Benzinga · 02/23 13:14
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting....
GlobeNewswire · 02/23 13:05
More
No Data
Learn about the latest financial forecast of ONVO. Analyze the recent business situations of Organovo Holding through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONVO stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
High3.000
Average3.000
Low3.000
Current 1.760
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q3 2020
Institutional Holdings
Institutions: 118
Institutional Holdings: 4.94M
% Owned: 56.67%
Shares Outstanding: 8.71M
TypeInstitutionsShares
Increased
2
9.19K
New
0
0
Decreased
12
156.37K
Sold Out
8
90.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Keith Murphy
President/Chief Financial Officer
Thomas Hess
Chief Scientific Officer
Jeffrey Miner
General Counsel/Secretary
Thomas Jurgensen
Director
Vaidehi Joshi
Independent Director
Douglas Cohen
Independent Director
David Gobel
Independent Director
Alison Milhous
Independent Director
Adam Stern
No Data
No Data
About ONVO
Organovo Holdings, Inc. is an early stage biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). It uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.

Webull offers kinds of Organovo Holdings Inc stock information, including NASDAQ:ONVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONVO stock methods without spending real money on the virtual paper trading platform.